Shots:

• Alexion to acquire Syntimmune for $1.2B in cash- including an upfront payment of $400M- with additional milestone payments of up to $800M. The transaction is expected to close in Q4’18
• Alexion to get the SYNT001 through this acquisition- which a humanized monoclonal antibody- which inhibits the binding of FcRn with Immunoglobulin G (IgG) and IgG immune complexes. It is being developed for the treatment of IgG-mediated rare diseases
• SYNT001 is currently tested in P-Ib/IIa studies for warm autoimmune hemolytic anemia (WAIHA) and pemphigus vulgaris (PV) or pemphigus foliaceus (PF) and has been validated in rapid IgG reduction

Ref: Alexion | Image: Syntimmune